Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
about
Linking uracil base excision repair and 5-fluorouracil toxicity in yeastCancer drug resistance: redox resetting renders a wayThymidine Phosphorylase in Cancer; Enemy or Friend?Newer therapies for the treatment of metastatic breast cancer: a clinical updatePharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next DecadeSensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugsA polymeric prodrug of 5-fluorouracil-1-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrierPhase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathwayMimicking damaged DNA with a small molecule inhibitor of human UNG2.Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy.Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.How multi-organ microdevices can help foster drug developmentBreast carcinoma with choriocarcinomatous features: a case report and review of the literature.Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives.Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil5-Fluorouracil derivatives: a patent review.A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer.Polyethylenimine-cyclodextrin-tegafur conjugate shows anti-cancer activity and a potential for gene delivery.Variability in the anti-tumor effect of tegafur-uracil depending on histologic types of lung cancer.Effects of American ginseng on pharmacokinetics of 5-fluorouracil in ratsRepurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial InfectionsEarly changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm.Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancerCancer stem cells and chemoresistance: The smartest survives the raid'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents.A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure.Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers.Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage.Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.Safety of capecitabine: a review.
P2860
Q25257142-2AD9B2B6-0918-427F-B559-FB90EC7EDA06Q26750753-22451036-27CD-43CA-9172-099AA5B76005Q26795650-435D9EB9-06F9-42F9-9E22-979244CB9849Q26865260-E3A0C784-9DC0-4CC3-BACC-AE6555AFFEF7Q28392069-A7FA247F-C634-4FFC-A617-FD3C6BC3F168Q28536754-2152DE46-ED91-40C8-BA56-8D42E701F591Q28544909-96DE5B4A-DA24-4DFA-8B9E-8EE435696BABQ30834530-0096ADF6-6B3F-4CEB-BC24-4F253DFE796DQ33261442-D18BBA96-CFAD-4605-B1AA-06A52ECD4B76Q33398998-AECF8350-7424-468A-88D3-AE564AED2EF3Q33416158-06CB2CEE-6939-4566-9E44-E19681E6DD19Q33428967-7ED39CDB-DDB2-4CD2-9D35-035238A611DEQ33430494-1B98811F-FAF7-4D9A-9D98-62C22DD5D3EDQ33437668-95A4EE0F-63C4-4698-9315-BD3E4E641E17Q33522017-19B7EACC-4AAA-47A6-9A75-26B29AAA2990Q33684453-03682838-D3A4-490E-8B80-CBE9017A844EQ33751177-A1750CE4-8424-428B-9A38-E575FCBDABCAQ33893475-5BEF1894-5840-4C84-B8DD-1C701709F19DQ34000141-B9116137-F386-4BB5-ACF4-4B15873FC1DFQ34074415-B35B49CA-E73C-4EF9-841B-CC6D3FAABD81Q34088371-0543F0E9-23A9-402A-9A33-9E8321A96DF6Q34253978-45D9A96B-04DC-4F87-9825-B065D8BF5557Q35033392-D891D686-76C5-4446-9C81-2F2BE72BF3C0Q35041996-5C13BA1D-07AE-43EF-9A25-66EBF6803618Q35199161-4005BC7C-EDA9-4127-94C3-F3C5A2E7644BQ35290541-34072427-1B37-413E-B662-AFE88D97D501Q35359878-0253C187-E60A-48C9-B2B1-68539E0E24CEQ35626649-AC439FBA-8BF5-42EB-B001-CB758D433584Q35812742-869C50CC-7CBE-4FA6-87CB-547EF1C5E8BAQ35850360-75C97487-5E5B-49C1-8E72-4F6A349B30E7Q36187034-E50CF2FB-88D0-441E-8BDB-B74E064ACFB7Q36609741-053B73EC-71A1-4B1A-B5B1-7969643EDEA5Q36730432-DF9A3684-CF48-4EC2-ACAA-79CD4AAB91B6Q36746390-20AB8563-EBE6-4148-965A-957E714B5006Q37294590-EC50F026-D76F-41C4-BE41-B0118F7344D6Q37327880-97ABFF5B-B88D-4132-B52D-027B594BF6F5Q37337130-D670FF92-44B4-480E-B574-34D59501930CQ37644861-4D789BF4-A3BF-40C7-89F0-5663BAB975E4Q37728873-1523AD90-CEA7-40D3-8C39-3CA79AC7853FQ37781051-22424AA3-ACDE-4C77-B4E1-DA4A36C0BEA7
P2860
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@ast
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@en
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@nl
type
label
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@ast
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@en
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@nl
prefLabel
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@ast
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@en
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@nl
P1433
P1476
Clinical studies of three oral ...... citabine, UFT, S-1): a review.
@en
P2093
M Malet-Martino
P304
P356
10.1634/THEONCOLOGIST.7-4-288
P577
2002-01-01T00:00:00Z